Haemic^®

Therapeutic Segment:
Anti-fibrinolytic

Generic Name:
Tranexamic Acid

Indication:
Hemorrhagic tendency considered to involve systemically exacerbated fibrinolysis (leukemia, hypoplastic anemia, purpura or abnormal hemorrhages during or after operation). Abnormal bleeding considered to involve locally exacerbated fibrinolysis (Pulmonary, nasal, genital, or renal hemorrhages or abnormal hemorrhages during or after prostate surgery). Symptoms such as erythema, swelling or itchiness in the following diseases: Eczema or similar diseases, urticarial, drug rash or toxic exanthema. Symptoms such as pharyngodynia, redness, hyperemia or swelling in the following diseases: Tonsillitis, pharyngo-laryngitis. Pain in the oral cavity or mucosal aphtha in cases of stomatitis. Tranexamic acid Injection is indicated in patients with haemophilia for short-term use (two to eight days) to reduce or prevent haemorrhage and reduce the need for replacement therapy during and following tooth extraction, menorrhagia and metrorrhagia, gynecological surgery or disorders of obstetric origin, thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery.

Formulation: